Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KERN Akerna		$5.89	$0.17 ▼ $6.40	$64.92M	3.02	339,022 shs	70,795 shs
MREO Mereo BioPharma Group	$1.70 +3.0%	$2.09	$1.47 ▼ $5.02	$270.30M	0.47	1.36 million shs	1.52 million shs
NMRA Neumora Therapeutics	$1.62 -1.2%	$1.38	$0.61 ▼ $17.19	$262.35M	2.91	1.13 million shs	338,797 shs
PBYI Puma Biotechnology	$5.25 +0.6%	$3.74	$2.22 ▼ $6.07	$264.45M	1.3	899,073 shs	669,767 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KERN Akerna	0.00%	0.00%	0.00%	0.00%	0.00%
MREO Mereo BioPharma Group	0.00%	-2.30%	-2.30%	-24.11%	-62.14%
NMRA Neumora Therapeutics	0.00%	-0.61%	-29.26%	+138.34%	-86.63%
PBYI Puma Biotechnology	0.00%	-8.38%	+54.41%	+62.54%	+94.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KERN Akerna	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	1.9341 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	0.0
NMRA Neumora Therapeutics	2.362 of 5 stars	3.1	3.0	0.0	0.0	1.4	2.5	0.6
PBYI Puma Biotechnology	4.097 of 5 stars	3.5	1.0	0.0	0.0	2.7	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KERN Akerna	0.00	N/A	N/A	N/A
MREO Mereo BioPharma Group	3.20	Buy	$7.20	323.53% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	340.92% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	33.33% Upside

Current Analyst Ratings Breakdown

Latest KERN, PBYI, NMRA, and MREO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KERN Akerna	$13.65M	0.00	N/A	N/A	($1.52) per share	0.00
MREO Mereo BioPharma Group	$10M	27.03	N/A	N/A	$0.34 per share	5.00
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.13 per share	N/A
PBYI Puma Biotechnology	$230.50M	1.15	$0.85 per share	6.16	$2.08 per share	2.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KERN Akerna	-$79.06M	-$7.10	N/A	N/A	N/A	-339.99%	N/A	-113.03%	N/A
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-80.00%	-66.94%	11/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.57	0.00	N/A	N/A	N/A	-98.95%	-87.68%	11/11/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.98	5.36	13.82	N/A	20.38%	53.15%	23.51%	11/6/2025 (Estimated)

Latest KERN, PBYI, NMRA, and MREO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$7.80 million	$0.50 million
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KERN Akerna	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KERN Akerna	N/A	0.10	0.10
MREO Mereo BioPharma Group	N/A	8.13	8.13
NMRA Neumora Therapeutics	0.11	10.54	10.54
PBYI Puma Biotechnology	0.10	1.73	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KERN Akerna	21.97%
MREO Mereo BioPharma Group	62.83%
NMRA Neumora Therapeutics	47.65%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
KERN Akerna	1.20%
MREO Mereo BioPharma Group	5.50%
NMRA Neumora Therapeutics	26.80%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KERN Akerna	112	10.35 million	10.23 million	No Data
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable
PBYI Puma Biotechnology	200	50.37 million	38.64 million	Optionable

KERN, PBYI, NMRA, and MREO Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy Rating

August 18, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 16, 2025 | marketbeat.com

Additional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings

August 15, 2025 | finance.yahoo.com

Puma Biotechnology Reports Strong Q2 2025 Earnings

August 13, 2025 | msn.com

Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT

August 12, 2025 | msn.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

August 12, 2025 | zacks.com

Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?

August 12, 2025 | zacks.com

Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

August 10, 2025 | finance.yahoo.com

Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Mackenzie Financial Corp Acquires 79,060 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 9, 2025 | marketbeat.com

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

August 8, 2025 | zacks.com

Puma (PBYI) Q2 Revenue Rises 11%

August 8, 2025 | fool.com

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago

August 2, 2025 | finance.yahoo.com

Puma Biotechnology (PBYI) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

July 30, 2025 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 24, 2025 | businesswire.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in Stock

July 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KERN, PBYI, NMRA, and MREO Company Descriptions

Akerna NASDAQ:KERN

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

Mereo BioPharma Group NASDAQ:MREO

$1.70 +0.05 (+3.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.71 +0.01 (+0.82%)

As of 08/22/2025 07:50 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Neumora Therapeutics NASDAQ:NMRA

$1.62 -0.02 (-1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.02 (+1.23%)

As of 08/22/2025 07:57 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Puma Biotechnology NASDAQ:PBYI

$5.25 +0.03 (+0.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.26 +0.01 (+0.29%)

As of 08/22/2025 06:28 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time